Takeda Pharmaceuticals logo - 2023

Takeda announces preliminary ERT trial results

Takeda announces preliminary ERT trial results Early results not as positive as hoped for Takeda Pharmaceuticals announced that a preliminary look at the results of their recently completed phase-IIb trial of their TAK-611 ERT (enzyme replacement therapy) for MLD “topline results … did not meet primary and secondary endpoints.” The company is analyzing the results and […]

Takeda announces preliminary ERT trial results Read More »